These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 6138036
21. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). Lui MS, Faderan MA, Liepnieks JJ, Natsumeda Y, Olah E, Jayaram HN, Weber G. J Biol Chem; 1984 Apr 25; 259(8):5078-82. PubMed ID: 6143752 [Abstract] [Full Text] [Related]
22. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P, Heerema N, Weber G, Hoffman R. Cancer Res; 1989 Jul 01; 49(13):3696-701. PubMed ID: 2567208 [Abstract] [Full Text] [Related]
24. Tiazofurin: biological effects and clinical uses. Tricot G, Jayaram HN, Weber G, Hoffman R. Int J Cell Cloning; 1990 May 01; 8(3):161-70. PubMed ID: 2189014 [Abstract] [Full Text] [Related]
25. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Franchetti P, Grifantini M. Curr Med Chem; 1999 Jul 01; 6(7):599-614. PubMed ID: 10390603 [Abstract] [Full Text] [Related]
26. Tiazofurin and selenazofurin induce depression of cGMP and phosphatidylinositol pathway in L1210 leukemia cells. Parandoosh Z, Robins RK, Belei M, Rubalcava B. Biochem Biophys Res Commun; 1989 Oct 31; 164(2):869-74. PubMed ID: 2554903 [Abstract] [Full Text] [Related]
27. Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-beta-D-ribofuranosylselenazole-4-carboxamide. Lucas DL, Robins RK, Knight RD, Wright DG. Biochem Biophys Res Commun; 1983 Sep 30; 115(3):971-80. PubMed ID: 6138039 [Abstract] [Full Text] [Related]
28. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Sladek NE, Landkamer GJ. Cancer Res; 1985 Apr 30; 45(4):1549-55. PubMed ID: 3978623 [Abstract] [Full Text] [Related]
29. Synthesis and antitumor activity of 2-beta-D-ribofuranosylselenazole-4- carboxamide and related derivatives. Srivastava PC, Robins RK. J Med Chem; 1983 Mar 30; 26(3):445-8. PubMed ID: 6827564 [Abstract] [Full Text] [Related]
30. Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193). Jayaram HN, Cooney DA, Glazer RI, Dion RL, Johns DG. Biochem Pharmacol; 1982 Aug 01; 31(15):2557-60. PubMed ID: 7126269 [No Abstract] [Full Text] [Related]
31. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses. Huggins JW, Robins RK, Canonico PG. Antimicrob Agents Chemother; 1984 Oct 01; 26(4):476-80. PubMed ID: 6151377 [Abstract] [Full Text] [Related]
32. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase. Sokoloski JA, Blair OC, Sartorelli AC. Cancer Res; 1986 May 01; 46(5):2314-9. PubMed ID: 2870796 [Abstract] [Full Text] [Related]
33. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA. Biochem Pharmacol; 1982 Dec 01; 31(23):3839-45. PubMed ID: 6130768 [Abstract] [Full Text] [Related]
34. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. Finlay GJ, Ching LM, Wilson WR, Baguley BC. J Natl Cancer Inst; 1987 Aug 01; 79(2):291-6. PubMed ID: 3474463 [Abstract] [Full Text] [Related]
35. Antitumor activity of pyrazofurin in combination with 5-azacytidine against murine P388 and L1210 leukemias and colon carcinoma 26. Chiuten DF, Muggia FM, Johnson RK. Cancer Treat Rep; 1979 Aug 01; 63(11-12):1857-62. PubMed ID: 93512 [No Abstract] [Full Text] [Related]
36. The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG. Biochem Pharmacol; 1982 Jun 01; 31(11):2133-6. PubMed ID: 6126195 [No Abstract] [Full Text] [Related]
37. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells. Olah E, Natsumeda Y, Ikegami T, Kote Z, Horanyi M, Szelenyi J, Paulik E, Kremmer T, Hollan SR, Sugar J. Proc Natl Acad Sci U S A; 1988 Sep 01; 85(17):6533-7. PubMed ID: 2901100 [Abstract] [Full Text] [Related]
38. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. Balzarini J, Karlsson A, Wang L, Bohman C, Horská K, Votruba I, Fridland A, Van Aerschot A, Herdewijn P, De Clercq E. J Biol Chem; 1993 Nov 25; 268(33):24591-8. PubMed ID: 7901217 [Abstract] [Full Text] [Related]
39. Targets and markers of selective action of tiazofurin. Weber G, Natsumeda Y, Pillwein K. Adv Enzyme Regul; 1985 Nov 25; 24():45-65. PubMed ID: 2424286 [Abstract] [Full Text] [Related]
40. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells. Zhen W, Jayaram HN, Marquez VE, Goldstein BM, Cooney DA, Weber G. Biochem Biophys Res Commun; 1991 Oct 31; 180(2):933-8. PubMed ID: 1683233 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]